side effects of glp-1 medication Adverse class drugs. Gastrointestinal issues are GLP-1 medication side effects for

The cumulative incidence was 8.9% for semaglutide and 1.8% for the non-GLP-1 RA group over 36 months

GLP-1 functions as an immune modulator because it controls macrophage polarization and T-cell functions [12,13]

48 The drug with the trade name Victoza is approved for this indication

A RECENT study has identified a potential link between the use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), and an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes (T2D) or those who are overweight or obese

That translates to fewer sudden cravings and more balanced hunger cues over the course of a day

These recommendations do not replace clinical judgement and are due for review in December of 2024